Compare FINV & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | AMPH |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 971.8M |
| IPO Year | 2017 | 2005 |
| Metric | FINV | AMPH |
|---|---|---|
| Price | $4.83 | $20.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.10 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 862.8K | 615.3K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $10.58 | $4.64 |
| P/E Ratio | ★ $3.87 | $150.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $16.65 |
| 52 Week High | $10.90 | $31.26 |
| Indicator | FINV | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 58.80 |
| Support Level | $4.67 | $18.92 |
| Resistance Level | $5.23 | $24.61 |
| Average True Range (ATR) | 0.16 | 0.83 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 39.11 | 98.15 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.